Kevin Rodriguez+FollowModerna’s RSV Shot Just Got a Big BoostModerna’s RSV vaccine just scored FDA approval for younger adults (18-59) with health issues—previously, it was only for those 60+. The move comes as RSV risks for under-60s are often overlooked, but a ton of people in that group have conditions that put them at risk. Meanwhile, vaccine policy is getting a shake-up with RFK Jr. bringing in new advisors (some anti-vax!), and Moderna’s stock is feeling the heat. Big pharma drama and health news all in one! #Moderna #RSV #FDA #Health #BodyHealth90Share
rmartinFollowingModerna’s RSV Shot Faces CDC DramaModerna just got the green light for its RSV vaccine in younger at-risk adults, but now there’s drama: a new CDC panel (with some anti-vax vibes) might not back it. Their shares dropped, and everyone’s wondering if this new group will actually recommend the shot. Meanwhile, rival vaccine makers are feeling the heat too. Big pharma plot twist, anyone? #Moderna #RSVvaccine #CDC #Health #BodyHealth100Share
Spencer Brewer+FollowModerna’s New Vax Gets Green Light!Moderna just scored FDA approval for its next-gen COVID-19 shot, mNEXSPIKE—even with all the investor drama and rumors flying around. This new vax is for adults 65+ and anyone 12-64 with health risks, and it’s got some cool upgrades: lower dose, longer shelf life, and easier storage than Spikevax. Despite all the chatter about changing vaccine guidelines, the CDC still recommends COVID shots for healthy kids (if parents/doctors agree). Big pharma drama, but Moderna’s moving forward! #Moderna #COVID19 #VaccineNews #Health10Share
nheath+FollowModerna’s New Covid Shot: What’s the Deal?Moderna just scored FDA approval for a new Covid vaccine, but there’s a catch—it’s only for folks 65+ or those 12-64 with health risks. The new shot, mNexspike, uses just a fifth of the dose of their old vaccine but still packs a punch. It’s not replacing the OG shot, just giving high-risk people another option. Basically, it’s a big move for next-gen vaccines, but don’t expect to see it everywhere just yet! #CovidVaccine #Moderna #FDA #Health1518Share
Christian Boone+FollowModerna Drops a New COVID Shot—But There’s a CatchModerna just got FDA approval for a new COVID-19 vaccine, mNexspike, but it’s not for everyone. This next-gen shot uses a much lower dose and is only for adults 65+ or people 12-64 with health risks. It’s not replacing the old vax—just adding another option. The twist? These limits are new for the U.S., and some say it’s politics, not science, driving the change. What do you think: smart move or too cautious? #COVID19 #Moderna #VaccineNews #Health925Share
peterfoster+FollowWhy the Feds Just Ghosted ModernaHeads up: The government just pulled the plug on a $766 million deal with Moderna for a bird flu vaccine. Translation? No more big bucks for Moderna’s new shot, even though early tests looked good. The reason: officials want to back tried-and-true vaccine methods, not just the latest tech. If you’re counting on quick shots in a future outbreak, this could mean fewer options—and maybe longer waits. Stay tuned for what Moderna does next! #VaccineNews #Moderna #BirdFlu #Business2511Share
Spencer Brewer+FollowModerna’s Combo Vax Hits a RoadblockModerna just yanked its FDA application for their much-hyped combo flu/COVID shot, even after saying it worked better than current vaccines. Turns out, the FDA wants more data, so Moderna’s pushing approval back to 2026 and deprioritizing the shot for now. Their stock dropped 4.5% on the news. They’ll try again later this year when more trial results come in. Meanwhile, the FDA’s getting stricter on vaccine approvals, and Pfizer’s racing ahead with its own combo vax. Wild times in vaccine land! #Moderna #VaccineNews #Biotech #FDA #COVID19 #Health10Share
Stephanie Snow+FollowFDA Shakes Up COVID Booster RulesBig change alert: The FDA just announced they’ll require actual clinical trials (not just immune response data) before approving new COVID booster shots for healthy people under 65. If you’re high-risk or over 65, you’ll still get access based on immune response. But for the rest of us? The bar’s higher—think gold-standard, randomized trials. Vaccine stocks like Moderna and Novavax jumped on the news. Is this the start of a new era for vaccine approvals? #COVID19 #FDA #VaccineUpdate #HealthNews #Moderna #Health100Share
Adam Cox+FollowOne Shot for Both Flu & COVID?A new study found that Moderna’s combo flu and COVID-19 vaccine (mRNA-1083) works just as well—if not better—than getting each shot separately for adults 50+. Not only did it trigger strong immune responses for both viruses, but it could mean fewer jabs next fall. Downside? Some folks had more side effects than with the usual vaccines. Would you go for a 2-in-1 shot if it meant less hassle? #VaccineNews #HealthUpdate #FluShot #COVID19 #Moderna #Health28183Share
Allison Bauer+FollowModerna’s Combo Shot DramaModerna’s new super-vaccine could make flu and covid season way easier—one shot, double the protection! Early trial results look awesome, but now FDA politics might slow everything down. New rules could mean more red tape, and some experts say it’s unnecessary and could even put people at risk. Imagine waiting years for a vaccine that’s already proven to work. Why does science always get tangled up in politics? #Moderna #VaccineNews #mRNA #FluShot #Covid19 #ScienceVsPolitics #Health00Share
